.jpeg)
2026-04-10 05:05:56
Ibrutinib, a BTK inhibitor, targets mantle cell lymphoma, chronic lymphocytic leukemia, and other blood cancers by blocking the B-cell receptor pathway. Monotherapy or combination regimens improve outcomes, while managing risks such as bleeding and infections.
2026-04-10 04:56:03
Axitinib, a targeted therapy, demonstrates significant efficacy in advanced renal cell carcinoma (RCC). Combining with immunotherapy or as monotherapy, it offers innovative first-line and second-line treatment approaches, effectively prolonging survival and improving quality of life while managing potential side effects.
2026-04-09 05:56:04
Trametinib, an oral selective MEK1/2 inhibitor, in combination with dabrafenib revolutionizes treatment for BRAF-mutant melanoma, NSCLC, and rare cancers, offering targeted efficacy and manageable safety profile.
2026-04-09 05:45:58
Pirtobrutinib, an innovative non-covalent BTK inhibitor, provides a treatment option for patients with relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), featuring a unique mechanism and manageable safety profile.
2026-04-09 05:22:20
This article systematically reviews the basic pharmaceutical properties, anti-tumor mechanism of action, approved indications, standard dosage and administration, pre-infusion preparation, and adverse event management of Sacituzumab Govitecan, providing a professional and comprehensive medication reference for oncology patients and clinical healthcare providers.
2026-04-07 04:45:06
The drug properties and mechanism of action of Fulvestrant (brand name Faslodex), systematically sorts out its indications, standard dosage, dose adjustment rules, adverse reactions and safety precautions for single-agent and combined treatment of breast cancer, providing professional reference for clinical diagnosis and treatment as well as patient medication.
2026-04-03 01:52:29
Adagrasib (brand name Krazati) is a highly selective oral KRAS G12C inhibitor, approved by the U.S. FDA for the treatment of KRAS G12C-mutated locally advanced/metastatic non-small cell lung cancer and colorectal cancer. It features excellent blood-brain barrier penetration and a long half-life, providing a precise anti-tumor option for patients with advanced solid tumors.
2026-04-01 04:22:07
Osimertinib (brand names Tagrisso/Tarceva), developed by AstraZeneca (UK), is a third-generation EGFR-TKI that selectively inhibits EGFR T790M, L858R, and exon 19 deletion mutations to block cancer cell signaling. It is widely used for EGFR-mutant non-small cell lung cancer (NSCLC).
2026-04-01 04:06:04
Published in The New England Journal of Medicineon March 25, 2026, the ATOMIC study by Dr. Frank A. Sinicrope’s team at Mayo Clinic demonstrated that atezolizumab combined with mFOLFOX6 chemotherapy significantly extended disease-free survival (DFS) in patients with dMMR stage III colon cancer, providing key evidence for immunotherapy applicability in this population.
2026-03-31 02:36:04
This article dissects the fundamental differences between Dostarlimab (PD-1 inhibitor) and Secukinumab (IL-17A antagonist) across mechanisms, indications, efficacy metrics, and safety profiles, emphasizing their distinct roles in oncology and autoimmune diseases.
2026-03-30 07:00:34
Lorlatinib, developed by Pfizer, is a groundbreaking third-generation ATP-competitive macrocyclic tyrosine kinase inhibitor targeting ALK and ROS1 mutations. With superior blood-brain barrier penetration and activity against resistant mutations, clinical data demonstrates unprecedented PFS超过3 years in frontline treatment, intracranial response rate of 83.3%, and transformative outcomes for advanced NSCLC patients. Explore its mechanism, global clinical evidence, administration guidelines, and AE management strategies.
2026-03-17 07:23:12
Records the complete treatment journey of an ALK-positive non-small cell lung cancer patient using Brigatinib, covering initial medication reactions, side effect management, efficacy evaluation, and lifestyle adjustments, providing real reference for similar patients.
